{"id":43886,"date":"2026-03-19T18:26:20","date_gmt":"2026-03-19T18:26:20","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/43886\/"},"modified":"2026-03-19T18:26:20","modified_gmt":"2026-03-19T18:26:20","slug":"novo-nordisks-high-dose-wegovy-approved-in-the-u-s","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/43886\/","title":{"rendered":"Novo Nordisk\u2019s high-dose Wegovy approved in the U.S."},"content":{"rendered":"

A high-dose version of Novo Nordisk\u2019s injectable obesity drug Wegovy received U.S. approval, the company said Thursday, providing it with a new catalyst as it tries to claw back market share with its weight loss treatments.<\/p>\n

The therapy was approved under a new voucher program that was set up by Food and Drug Administration Commissioner Marty Makary and that was intended to accelerate review of drugs that align with national priorities. Novo received the voucher as part of its deal<\/a> with the Trump administration late last year to lower prices of its obesity medicines in certain settings.<\/p>\n

\t\t\t\"\"\t\t<\/p>\n

\t\t\t\t\"\"\/
\n\t\t\t\tSTAT Plus: Eli Lilly\u2019s \u2018triple-G\u2019 drug leads to significant blood sugar, weight reductions in diabetes trial<\/a><\/p>\n

Novo was first to open up the booming obesity market with Wegovy, but it\u2019s fallen behind Eli Lilly in recent years<\/a>, and it\u2019s not clear how much high-dose Wegovy will help it become more competitive again.<\/p>\n

STAT+ Exclusive Story<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\"STAT+\"\/<\/p>\n

\t\t\t\t\t
\n\t\t\t\t\t\t\"STAT+\"\/
\n\t\t\t\t\t<\/a><\/p>\n

\t\t\t\tThis article is exclusive to STAT+ subscribers
\n\t\t\t\tUnlock this article \u2014 plus daily coverage and analysis of the pharma industry \u2014 by subscribing to STAT+.<\/p>\n

Already have an account? Log in<\/a><\/p>\n

\t\t\t\t\t\tIndividual plans<\/p>\n

\t\t\t\t\t\tGroup plans<\/p>\n

\t\t\t\tView All Plans<\/a><\/p>\n

\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n

\t\t\t\t\tSubscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"A high-dose version of Novo Nordisk\u2019s injectable obesity drug Wegovy received U.S. approval, the company said Thursday, providing…\n","protected":false},"author":2,"featured_media":3336,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[2759,276,272,357,358,359,280],"class_list":["post-43886","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-biotechnology","tag-eli-lilly","tag-novo-nordisk","tag-obesity","tag-pharmaceuticals","tag-stat","tag-weight-loss"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116257251993651709","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/43886","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=43886"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/43886\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/3336"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=43886"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=43886"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=43886"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}